오스티오뉴로젠 (OSTEONEUROGEN)

NOTICE

게시물이 없습니다.

About us

Osteoneurogen (ONG) is based on a deep understanding of the mechanisms behind fibrosis on a global scale.
Further, ONG was founded primary to discover, clinical develop, co-research, license in & out, produce, and commercialize
new drug pipelines that are innovative than the existing drugs that target fibrosis, considered one of the highest medically
unmet need. We have a vision that grow into a world class bio company developing fibrosis drugs through
continuous innovation & development efforts.

Pipeline

Highlights

Developing a first-class drug in IPF

Idiopathic Pulmonary Fibrosis(IPF) is a type of chronic scarring lung disease with an average life expectancy of 5-years following diagnosis. There is a huge medical unmet needs in IPF market because there is no pertinent drug to date. So we are developing a first-class drug in IPF using new small-molecule candidate with a novel TGF-beta inhibition mechanism to solve this problem.

Discovering a game changer in NASH

Nonalcoholic steatohepatitis(NASH), which affects about 5% of the US population, is an inflammatory fibrotic liver disease caused by aggravation of nonalcoholic fatty liver disease. In the absence of standard drugs, our anti-fibrosis pipeline is drawing significant attention by meaningfully reducing the NAFLD activity score(NAS) in STAM model assay.

Contact Our Company

We are taking historical steps to give hope to the patients
around the world through overcoming fibrosis.